News Article | May 12, 2017
Mediaplanet today announces the launch of this May’s edition of “Clinical Trials.” This campaign will educate doctors, physicians, nurses, and allied healthcare professionals on the benefits of conducting a clinical trial, while honing in on the proper and most effective ways to improve the process, ultimately leading to an increase in completed trials, treatments, and live saving discoveries. Only around 32% of drugs have a probability into making it to phase 3 trials, and only 1 in 10 drugs actually make it to the market. This means that the time, effort, and dollars that are being spent (800k-1.4B) for clinical trials are not panning out as plan, which causes hesitation in their conduction. There are several factors leading to the incompletion of a clinical trial. Ensuring the clinical trial is planned properly, leads to a higher success rate of the trial.The need for more participants and better planned clinical trials is crucial. The print component of “Clinical Trials” is distributed within today’s edition of USA Today in New York, Boston, Washington/Baltimore, Phoenix, and the Carolinasmarkets, with a circulation of approximately 250,000 copies and an estimated readership of 750,000. The digital component is distributed nationally, through a vast social media strategy, and across a network of top news sites and partner outlets. To explore the digital version of the campaign, click here. Cancer survivor and clinical trial activist T.J. Share graces the cover of the print publication. Through an exclusive interview on the interior, T.J. shares his story on how participating in clinical trials saved his life. T.J. talks about the power of clinical trials and how others can educate themselves on these life-saving studies. T.J. encourages all to consider clinical trials as an option, he says “when it comes down to it, we are all patients at some point, so we should know what all of our options are before making a decisions.” This campaign was made possible with the support of the Center for Information on Clinical Research Participation (CISCRP), Association of Clinical Research Professionals (ACRP), Coalition for Clinical Trials Awareness(CCTA), Clinical Trials Transformation Initiative (CTTI), QST Consultations, TransCelerate BioPharma Inc., Biogen, Merck, Pfizer, Janssen, CureForward, and PerkinElmer. About Mediaplanet Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.
News Article | May 4, 2017
An unmanned aerial vehicle (UAV) equipped with light detection and ranging (LiDAR) technology is being tested to document cut-and-fill work on a $74-million interchange in Contra Costa County, Calif. With an equipment cost of about $150,000, the drone’s high-resolution data-capture technology will monitor the movement of 150,000 cu yd of fill, ensuring the estimated $1-million to $2-million worth of earthwork goes as efficiently as possible. “Five years ago, there was no way we could have put LiDAR on a UAV,” says Ed Greutert, principal engineer with Alta Vista Solutions, which proposed testing the technology to the Contra Costa County Transportation Authority (CCTA). “Now, a number of manufacturers are making units that are far more advanced, weighing 4 kilograms [8 lb,13 oz] or less.” A French company, Yellowscan, provides the LiDAR. Weighing 3.5 pounds and consuming 15 watts of power, the device has a precision rate of 4 sq centimeters and boasts 5-sq-cm accuracy. The scans will be used to compare contractor performance versus the plan and identify potential areas of project and performance risk. The data will be used to verify fill-invoice amounts, track materials inventory, and support project scheduling and change-order documentation. It also will be used to monitor stormwater runoff and other environmental conditions, as well as identify potential safety risks and evaluate changes in existing structures that may be introduced during construction. Gathering the unusually high-resolution data initially involved the drone operator repeatedly adjusting to find the optimal height and speed in a trial-and-error process. “I’d say the biggest challenge we had is collecting the data we need to generate a bare-earth digital service model,” says Greutert. “During the first month, the data was not dense enough to use for our purposes.” Another challenge is handling the massive amounts of information. “We collected 100 gigabytes of LiDAR data,” says Greutert. “Moving that around and processing it … can take several hours or overnight. Then, you tweak something and rerun the model.” To be collected over the course of the two-year project in Brentwood, the data are expected not only to maximize efficiency of the earthmoving but also help the public to see each stage of construction, says Randell Iwasaki, executive director at CCTA. “Aerial views are hard to come by. Now, we can get a video of the progress of our project. We can take a look at environmentally sensitive areas. We can show that nobody’s in there—that we are treating those areas as promised. We can ‘fly a job’ after it rains to make sure the [runoff] control systems are working as they should.” Moreover, Iwasaki adds, using the drone means surveyors don’t have to stand in live traffic in harm’s way. “We are always looking for ways to be efficient and safer,” Iwasaki says. “Drones offer a golden opportunity. We can gather enough info from a drone, sensors, etcetera, so we know the taxpayers are getting their money’s worth.” The CCTA last fall awarded the $37-million construction contract to a joint venture of Brosamer & Wall Inc. and Bay Cities Paving & Grading. The project is the concluding chapter of the Highway 4 program, a $1-billion endeavour to improve mobility in the region.
News Article | June 12, 2017
REDWOOD CITY, Calif.--(BUSINESS WIRE)--HeartFlow, Inc. today announced that Blue Cross Blue Shield (BCBS) Association’s Evidence Street has issued a positive healthcare evidence review of the Company’s HeartFlow® FFRct. This non-invasive technology is the first to provide insight into both the extent of coronary artery disease (CAD) and the impact the disease has on blood flow to the heart. It combines anatomic information from a coronary CT angiogram and physiology from HeartFlow FFRct to enable clinicians to select an appropriate and personalized treatment for each patient. The Evidence Street review assessed the technical performance, diagnostic accuracy and clinical utility of HeartFlow FFRct and determined that it provides a meaningful improvement in net health outcome when used to guide the care of patients with stable chest pain who are at intermediate risk of CAD and are being considered for invasive coronary angiography. “This marks a major milestone achievement for HeartFlow and our FFRct technology because BCBS’s Evidence Street is among the world’s most rigorous health technology assessments and has significant global reach and influence,” said John H. Stevens, M.D., chief executive officer of HeartFlow. “With BCBS insuring one in three Americans, substantially more patients with suspected CAD in the United States who are part of BCBS plans will be able to access this innovative non-invasive technology. HeartFlow FFRct also could now more rapidly become the standard of care, potentially improving clinical outcomes and saving global healthcare systems billions of dollars annually.” Evidence Street provides healthcare technology evaluations for the BCBS Association, a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield companies that collectively provide healthcare coverage for 105 million Americans. Evidence Street’s assessment of HeartFlow FFRct, which is summarized in a 19-page report, concluded that “CCTA (coronary CT angiogram) with a selective FFRct strategy would likely lead to changes in management that would be expected to improve health outcomes by further limiting unnecessary ICA (invasive coronary angiography) testing.” Evidence Street joins a growing number of organizations that support the use of HeartFlow FFRct as part of the diagnostic and treatment pathway for CAD. Several payers, including Aetna, which covers more than 46 million lives, have issued positive coverage decisions. In February, the National Institute for Health and Care Excellence (NICE) of the U.K.’s National Health Service, which covers 59 million lives, issued positive guidance, recommending the technology to help determine the cause of stable chest pain in patients. NICE concluded that HeartFlow FFRct is safe, has a high level of diagnostic accuracy, and may avoid the need for invasive coronary angiography, which is associated with risks. NICE further concluded that, compared to all other tests, use of HeartFlow FFRct is the most cost-effective solution as it avoids unnecessary invasive tests and treatment. Additionally, the American College of Cardiology (ACC) and American Heart Association (AHA) recently released updated Appropriate Use Criteria for Coronary Revascularization in Patients with Stable Ischemic Heart Disease, which include the use of HeartFlow FFRct by healthcare providers in determining the appropriateness of revascularizations in many clinical scenarios. The HeartFlow FFRct process starts with data from a standard, non-invasive coronary CT angiogram from a patient. Leveraging deep learning, an advanced form of artificial intelligence, HeartFlow creates a personalized 3D model of the patient’s arteries. Powerful computer algorithms then solve millions of complex equations to simulate blood flow and assess the impact of blockages in the arteries. With this actionable information, the physician can determine the right course of action for the patient. HeartFlow FFRct has received regulatory approval and is commercially available in the United States, Canada, Europe and Japan. To date, more than 10,000 patients have benefitted from this technology. Coronary artery disease (CAD), also called coronary heart disease, is the leading cause of death for both men and women around the world. CAD develops when the arteries leading to the heart narrow, often because plaque builds up in the vessel walls. Narrowing of the arteries can reduce blood flow to the heart, causing angina (chest pain), myocardial infarction (heart attack) and death. CAD is one of the costliest medical diseases in the world today. HeartFlow, Inc. is a personalized medical technology company seeking to transform the way cardiovascular disease is diagnosed and treated. The company’s HeartFlow FFRct is the first available non-invasive solution that enables a physician to more accurately evaluate whether a patient has significant coronary artery disease (CAD) based on both anatomy (from coronary CT angiogram) and physiology (from HeartFlow FFRct). The solution, which leverages deep learning to create a personalized 3D model of the patient’s arteries, is well positioned to become an integral part of the standard of care for patients who are at risk for CAD because of its potential to improve clinical outcomes, improve the patient experience, and reduce the cost of care. The HeartFlow FFRct is available in the United States, Canada, Europe and Japan. For more information visit www.heartflow.com.
News Article | June 15, 2017
(PRLEAP.COM) JUNE 15, 2017 - CONCORD, Calif. First Transit announces that it has signed an agreement as the exclusive transit operator partner at GoMentum Station. The partnership will foster research and innovation in the field of shared autonomous vehicle (SAV) application and technology research.First Transit will join GoMentum Station and use the facility as a test site for innovative transit applications, including a pilot project with EasyMile and the Contra Costa Transportation Authority (CCTA) to deploy the first SAV shuttle on public roads in the United States. This pilot project, which began in late 2016, recently launched the second phase of testing at Bishop Ranch, an office park in San Ramon, California.First Transit is responsible for providing staffing, maintenance and operational support for the two SAV shuttles during the testing and deployment phases of the program."The partnership with GoMentum Station allows us to identify new mobility solutions for our customers using SAV technology," said Brad Thomas, president of First Transit. "We see the broad application of SAV technology as a great first and last mile solution plus countless other transportation challenges."GoMentum Station in Concord, California, is a 5,000-acre test facility where the CCTA and its partners are accelerating the next generation of transportation technologies. Named by the U.S. Department of Transportation as one of ten federally designated automated vehicle proving grounds, GoMentum Station is the largest secure test track of its kind."As a leader in innovative transportation solutions, we are proud to have First Transit as one of our exclusive collaboration partners at GoMentum Station," said Randell Iwasaki, Executive Director of CCTA. "The partnership with First Transit expands the international reach of GoMentum Station, and will provide a unique opportunity for multi-modal testing with a firm that specializes in transit operations. This will enable us to explore how automated vehicles can complement and enhance existing mobility options."About First Transit:First Transit, Inc. has 60 years of experience and is one of the largest private-sector providers of mobility solutions in North America moving more than 350 million passengers annually. First Transit, Inc. provides operation, management and consulting for more than 300 locations in 39 states, Canada, Puerto Rico, Panama and India for transit authorities, state departments of transportation, municipalities, hospitals, universities and private companies. First Transit employs more than 19,500 dedicated transit professionals. For additional information, please visit FirstTransit.com About GoMentum Station:GoMentum Station in Concord, California is where the Contra Costa Transportation Authority leads and facilitates a collaborative partnership among multiple automobile manufacturers; original equipment manufacturers and Tier 1 suppliers; communications suppliers; technology companies; researchers and academia; public agencies and other partners. At GoMentum Station, technology, innovation and commercialization will converge to define the next generation of transportation network infrastructure. More information about GoMentum Station is available at gomentumstation.net About EasyMile:EasyMile is a joint venture between a vehicle manufacturer (Ligier Group) and a high tech company specializing in services robotics (Robosoft). The company provides shared driverless transportation for the last mile that complements mass transportation solutions. This 'green' service addresses short distances that are too long to walk to, from a transport hub to a final destination where cars are either 'off limits' or where parking space is limited or non-existent. It also provides a service for short distances within confined sites. EasyMile autonomous vehicles operate either on demand or follow a set route calling at all stations.About the Contra Costa Transportation Authority:The Contra Costa Transportation Authority (CCTA) is a public agency formed by Contra Costa voters in 1988 to manage the county's transportation sales tax program and oversee countywide transportation planning efforts. CCTA is responsible for planning, funding and delivering critical transportation infrastructure projects and programs that connect our communities, foster a strong economy, increase sustainability, and safely and efficiently get people where they need to go. CCTA also serves as the county's designated Congestion Management Agency, responsible for putting programs in place to keep traffic levels manageable. More information about CCTA is available at ccta.net
News Article | February 21, 2017
LOS ANGELES - (Feb. 21, 2017) - A new study suggests testosterone treatments may increase the risk of heart disease in older men. It found a 20% increase in arterial plaque among men aged 65 and older who received testosterone replacement therapy for a year, according to the study published today in the Journal of the American Medical Association (JAMA). The multicenter study followed 138 men enrolled in the Testosterone Trials (TTrials), a National Institutes of Health (NIH) funded clinical research trial to determine if testosterone treatment of men aged 65 and older will help their walking, vitality, sexual function, memory, blood count and cardiovascular risk. The researchers reported that the men who received a placebo had just a 1% rise in plaque volumes, while the men who received the testosterone treatments for a year had a 20% increase in total coronary and noncalcified plaque volumes as measured with coronary computed tomographic arteriography (CCTA). "Heart disease remains the No. 1 cause of death in the U. S., and measuring coronary artery atherosclerosis has become a most effective method for evaluating cardiovascular risk," said Matthew J. Budoff, MD, a cardiologist who is an LA BioMed lead researcher and the primary author of the study. "While physicians are increasingly prescribing testosterone replacement for their older male patients, recent studies had reached conflicting conclusions about the potential cardiovascular risks. This finding of a significant increase in plaque volumes among men undergoing testosterone treatments indicates they may face a potentially increased risk of heart disease. However, longer-term research is needed to determine the actual risk." Dr. Budoff was the principal investigator for the study, and Drs. Ronald Swerdloff and Christina Wang, endocrinologists who are also LA BioMed lead researchers, were also investigators and authors of the study. It is one of four studies published today from the TTrials, a coordinated group of seven trials conducted by a team of researchers from LA BioMed and 12 other medical centers in the U.S., in partnership with the National Institute on Aging. "While our previous research has found some benefits from testosterone treatments, this latest study should provide important guidance for physicians and their patients," said Dr. Budoff. "Men who have underlying coronary artery disease or studies showing elevated arterial plaque levels should discuss carefully with their physicians the benefits and risks of testosterone therapy before initiating it or continuing the therapy." These results indicate the need for a larger and longer trial to determine actual risk of testosterone replacement. The study is one of four studies examining testosterone therapy that were published today in JAMA and JAMA Internal Medicine. In addition to the LA BioMed researchers, the authors of this study are: Susan S. Ellenberg, PhD; Cora E Lewis, MD, MSPH; Emile R Mohler III, MD; Nanette K Wenger, MD, MACC, MACP, FAHA; Shalender Bhasin, MD; Elizabeth Barrett-Connor, MD; Alisa Stephens-Shields, PhD; Jane A Cauley, DrPH; Jill P Crandall, MD; Glenn R Cunningham, MD; Kristine E Ensrud, MD, MPH; Thomas M. Gill, MD; Alvin M Matsumoto, MD; Mark E Molitch, MD; Rine Nakanishi, MD; Negin Nezarat, MD; Suguru Matsumoto, MD; Xiaoling Hou, MS; Shehzad Basaria, MD; Susan J. Diem, MD, MPH; Denise Cifelli, MS, and Peter J. Snyder, MD. Founded in 1952, LA BioMed is one of the country's leading nonprofit independent biomedical research institutes. It has approximately 100 principal researchers conducting studies into improved treatments and therapies for cancer, inherited diseases, infectious diseases, illnesses caused by environmental factors and more. It also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs. LA BioMed is academically affiliated with the David Geffen School of Medicine at UCLA and located on the campus of Harbor-UCLA Medical Center. For more information, please visit http://www.
News Article | November 29, 2016
CHICAGO - Researchers using coronary computed tomography angiography (CCTA) have found no association between light to moderate alcohol consumption and coronary artery disease (CAD), according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). Some previous studies have suggested that light alcohol consumption may actually reduce the risk for CAD. However, data regarding regular alcohol consumption and its association with the presence of CAD remains controversial. For the new study, researchers looked at alcohol consumption, type of alcohol consumed, and presence of coronary plaques using CCTA. "CCTA is an excellent diagnostic modality to noninvasively depict the coronary wall and identify atherosclerotic lesions," said study author Júlia Karády, M.D., from the MTA-SE Cardiovascular Imaging Research Group, Heart and Vascular Center at Semmelweis University in Budapest, Hungary. "Furthermore, we're able to characterize plaques and differentiate between several types. Prior studies used cardiovascular risk factors--like high cholesterol levels--and cardiovascular outcomes to study the effects of alcohol, but our study is unique in that we analyzed both drinkers and non-drinkers using CCTA, which may shed some light on how alcohol may or may not contribute to the development of fatty plaques in the arteries of the heart." The researchers studied 1,925 consecutive patients referred for CCTA with suspected CAD. Information on alcohol consumption habits was collected using questionnaires about the amount and type of alcohol consumed. Using an in-house reporting platform that contained the patients' clinical and CCTA data, researchers were able to assess the relationship between atherosclerosis, clinical risk factors and patient drinking habits. "About 40 percent of our patients reported regular alcohol consumption, with a median of 6.7 alcohol units consumed weekly," Dr. Karády said. One unit translates to approximately 2 deciliters (dl) or 6.8 fluid ounces of beer, 1 dl or 3.4 ounces of wine, or 4 centiliters (cl) or 1.35 ounces of hard liquor. The results showed that the amount of weekly alcohol consumption, whether light or moderate, was not associated with the presence of CAD. In addition, when researchers looked at different types of alcohol and the presence of coronary atherosclerosis, no associations were found. "When we compared consumption between patients who had coronary artery plaques and those who had none, no difference was detected," Dr. Karády said. "Evaluating the relationship between light alcohol intake (maximum of 14 units per week) and presence of CAD, we again found no association. Furthermore, we analyzed the effect of different types of alcohol (beer, wine and hard liquor) on the presence of CAD, but no relationship was found." Dr. Karády added that while no protective effect was detected among light drinkers, as previously thought, no harmful effects were detected either. The researchers are in the process of expanding the study to include more patients and perform further analyses. Independently of whether alcohol has any effect on the coronary arteries, moderate alcohol consumption has been associated with a number of potential side effects, including negative long-term effects on the brain and heart. Co-authors on this study were Balint Szilveszter, M.D., Zsofia D. Drobni, M.D., Marton Kolossvary, M.D., Andrea Bartykowszki, M.D., Mihaly Karolyi, M.D., Ph.D., Adam Jermendy, M.D., Alexisz Panajotu, M.D., Zsolt Bagyura, M.D., and Pal Maurovich-Horvat, M.D., Ph.D., M.P.H. Note: Copies of RSNA 2016 news releases and electronic images will be available online at RSNA.org/press16 beginning Monday, Nov. 28. RSNA is an association of more than 54,000 radiologists, radiation oncologists, medical physicists and related scientists, promoting excellence in patient care and health care delivery through education, research and technologic innovation. The Society is based in Oak Brook, Ill. (RSNA.org)
Ferreira J.A.M.,University of Coimbra |
Reis P.N.B.,CCTA |
Costa J.D.M.,University of Coimbra |
Richardson B.C.H.,CTA Ltd. |
Richardson M.O.W.,CTA Ltd.
Composites Part B: Engineering | Year: 2011
This paper presents the results of a current study concerned with the mechanical properties of a polypropylene binder resin, enhanced by nanoclay filler. The study was centred on the potential benefits obtained by the addition of specially surface treated nanoclays on the stiffness, toughness and also on static and fatigue strength. Specimens were produced by an injection moulding process with 3% in weight of nanoclay. Surface treatment of the nanoclay promotes a tendency to increase stiffness and tensile strength in comparison with composites filled by both commercial nanoclay and unfilled material. Nanoclay filling significantly improves absorbed impact energy in comparison with unfilled materials, but in contrast Gc values are significantly lower as consequence of the material embrittlement. Fatigue analysis shows that the materials tested in the present work exhibit high strain accumulation and stress release. Filled material show lower fatigue performance than unfilled polymer. However, surface treatment used on B3 composite promotes better clay dispersion and smaller particle size leading to a fatigue performance close to matrix polymer. © 2011 Elsevier Ltd. All rights reserved.
News Article | November 29, 2016
CHICAGO, Nov. 29, 2016 /PRNewswire-USNewswire/ -- Researchers using coronary computed tomography angiography (CCTA) have found no association between light to moderate alcohol consumption and coronary artery disease (CAD), according to a study being presented today at the annual meeting...
News Article | November 29, 2016
SAN FRANCISCO, Nov. 29, 2016 /PRNewswire/ -- The Metropolitan Transportation Commission (MTC), Caltrans, the Transportation Authority of Marin (TAM) and the Contra Costa Transportation Authority (CCTA) invite the public to a pair of open houses in Richmond on Thursday, Dec. 8 and in San...
News Article | November 30, 2016
Researchers using coronary computed tomography angiography (CCTA) have found no association between light to moderate alcohol consumption and coronary artery disease (CAD).